Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma


Diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma in adulthood, comprises multiple biologically and clinically distinct subtypes including germinal centre B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL1. Gene expression profile studies have shown that its most aggressive subtype, ABC-DLBCL, is associated with constitutive activation of the NF-κB transcription complex2. However, except for a small fraction of cases3, it remains unclear whether NF-κB activation in these tumours represents an intrinsic program of the tumour cell of origin or a pathogenetic event. Here we show that >50% of ABC-DLBCL and a smaller fraction of GCB-DLBCL carry somatic mutations in multiple genes, including negative (TNFAIP3, also called A20) and positive (CARD11, TRAF2, TRAF5, MAP3K7 (TAK1) and TNFRSF11A (RANK)) regulators of NF-κB. Of these, the A20 gene, which encodes a ubiquitin-modifying enzyme involved in termination of NF-κB responses, is most commonly affected, with 30% of patients displaying biallelic inactivation by mutations and/or deletions. When reintroduced in cell lines carrying biallelic inactivation of the gene, A20 induced apoptosis and cell growth arrest, indicating a tumour suppressor role. Less frequently, missense mutations of TRAF2 and CARD11 produce molecules with significantly enhanced ability to activate NF-κB. Thus, our results demonstrate that NF-κB activation in DLBCL is caused by genetic lesions affecting multiple genes, the loss or activation of which may promote lymphomagenesis by leading to abnormally prolonged NF-κB responses.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: The NF-κB pathway is active in ABC-DLBCL and in a smaller fraction of GCB-DLBCL.
Figure 2: Mutations and deletions of the A20 gene in ABC-DLBCL.
Figure 3: Reconstitution of A20 -null cell lines causes apoptosis and cell growth arrest via inhibition of NF-κB.

Accession codes

Primary accessions

Gene Expression Omnibus

Data deposits

The expression data and the 250K SNP data reported here have been deposited in the NCBI Gene Expression Omnibus (GEO) ( database (series accession number GSE12195 and GSE15127).


  1. 1

    Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000)

    ADS  CAS  Article  Google Scholar 

  2. 2

    Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861–1874 (2001)

    CAS  Article  Google Scholar 

  3. 3

    Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676–1679 (2008)

    ADS  CAS  Article  Google Scholar 

  4. 4

    Monti, S. et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105, 1851–1861 (2005)

    CAS  Article  Google Scholar 

  5. 5

    Savage, K. J. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102, 3871–3879 (2003)

    CAS  Article  Google Scholar 

  6. 6

    Wright, G. et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 100, 9991–9996 (2003)

    ADS  CAS  Article  Google Scholar 

  7. 7

    Ngo, V. N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106–110 (2006)

    ADS  CAS  Article  Google Scholar 

  8. 8

    Rawlings, D. J., Sommer, K. & Moreno-Garcia, M. E. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nature Rev. Immunol. 6, 799–812 (2006)

    CAS  Article  Google Scholar 

  9. 9

    Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nature Rev. Immunol. 2, 725–734 (2002)

    CAS  Article  Google Scholar 

  10. 10

    Hoffmann, A. & Baltimore, D. Circuitry of nuclear factor κB signaling. Immunol. Rev. 210, 171–186 (2006)

    Article  Google Scholar 

  11. 11

    Pomerantz, J. L. & Baltimore, D. Two pathways to NF-κB. Mol. Cell 10, 693–695 (2002)

    CAS  Article  Google Scholar 

  12. 12

    Coope, H. J. et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J. 21, 5375–5385 (2002)

    MathSciNet  CAS  Article  Google Scholar 

  13. 13

    Basso, K. et al. Tracking CD40 signaling during germinal center development. Blood 104, 4088–4096 (2004)

    CAS  Article  Google Scholar 

  14. 14

    Boone, D. L. et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nature Immunol. 5, 1052–1060 (2004)

    CAS  Article  Google Scholar 

  15. 15

    Lee, E. G. et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350–2354 (2000)

    ADS  CAS  Article  Google Scholar 

  16. 16

    Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694–699 (2004)

    ADS  CAS  Article  Google Scholar 

  17. 17

    Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175–179 (1997)

    ADS  CAS  Article  Google Scholar 

  18. 18

    Rothe, M., Sarma, V., Dixit, V. M. & Goeddel, D. V. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science 269, 1424–1427 (1995)

    ADS  CAS  Article  Google Scholar 

  19. 19

    Rothe, M., Wong, S. C., Henzel, W. J. & Goeddel, D. V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78, 681–692 (1994)

    CAS  Article  Google Scholar 

  20. 20

    Yamaguchi, K. et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270, 2008–2011 (1995)

    ADS  CAS  Article  Google Scholar 

  21. 21

    Gaidano, G. et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80, 1781–1787 (1992)

    CAS  PubMed  Google Scholar 

  22. 22

    Honma, K. et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosom. Cancer 47, 1–7 (2008)

    CAS  Article  Google Scholar 

  23. 23

    Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275–282 (2004)

    CAS  Article  Google Scholar 

  24. 24

    Karin, M. Nuclear factor-κB in cancer development and progression. Nature 441, 431–436 (2006)

    ADS  CAS  Article  Google Scholar 

  25. 25

    Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346–351 (2001)

    ADS  CAS  Article  Google Scholar 

  26. 26

    Novak, U. et al. The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas Blood . 10.1182/blood-2008-08-174110 (2009)

  27. 27

    Kato, M. et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 10.1038/nature07969 (this issue)

  28. 28

    Schmitz, R. et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. (in the press)

  29. 29

    Saito, M. et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12, 280–292 (2007)

    CAS  Article  Google Scholar 

  30. 30

    Pasqualucci, L. et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203, 311–317 (2006)

    CAS  Article  Google Scholar 

  31. 31

    Phan, R. T. & Dalla-Favera, R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432, 635–639 (2004)

    ADS  CAS  Article  Google Scholar 

  32. 32

    Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341–346 (2001)

    ADS  CAS  Article  Google Scholar 

  33. 33

    Falini, B. et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95, 2084–2092 (2000)

    CAS  PubMed  Google Scholar 

  34. 34

    Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)

    ADS  CAS  Article  Google Scholar 

  35. 35

    Lois, C., Hong, E. J., Pease, S., Brown, E. J. & Baltimore, D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868–872 (2002)

    ADS  CAS  Article  Google Scholar 

  36. 36

    Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267 (1996)

    ADS  CAS  Article  Google Scholar 

Download references


We thank P. Smith, P. Chadwick and the Molecular Pathology Facility of the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center for histology service; V. V. V. Murty and the HICCC Molecular Cytogenetics Service for assistance on the FISH analysis; the HICCC Flow Cytometry Facility for fluorescence-activated cell sorting; V. Miljkovic and J. Pack for help with the Affymetrix gene expression hybridization; U. Klein and D. Dominguez-Sola for suggestions; L. Menard for help with the mutation analysis; and G. Inghirami for the pWPI lentiviral vector. Automated DNA sequencing was performed at Genewiz Inc. L.P. is on leave from the Institute of Hematology, University of Perugia Medical School, Perugia, Italy. This work was supported by NIH grants P01 CA92625-07 (R.D.-F.), NIAID R01AI066116, the National Centers for Biomedical Computing NIH Roadmap initiative U54CA121852 (A.Ca.), and a Leukemia and Lymphoma Society SCOR grant (R.D.-F.). L.P. would like to dedicate this work to the memory of Enrico Pasqualucci.

Author Contributions L.P. and R.D.-F. designed the study. M.C., A.G. and Q.S. performed experiments; L.P. performed the A20 functional assays; W.K.L. and A.Ca. developed tools for genome-wide expression profile analysis; S.V.N. performed the FISH analysis; A.Ch. and G.B. analysed all immunohistochemistry data; A.Ch., G.B., F.B. and M.P. provided DLBCL samples; M.B., F.B. and M.S. performed SNP array analysis; L.P. designed experiments, coordinated the study, analysed data and wrote the manuscript, which was commented on by all authors.

Author information



Corresponding author

Correspondence to Laura Pasqualucci.

Supplementary information

Supplementary Information

This file contains Supplementary Methods, Supplementary Figures S1-S6 with Legends, Supplementary References and Supplementary Tables S1-S9. Supplementary Fig. 4 was amended on 9 July 2009. (PDF 2821 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Compagno, M., Lim, W., Grunn, A. et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing